Glaxo Operations UK Limited, trading as Glaxo Wellcome Operations (Manufacturing of unpackaged products, quality control)

The drug is intended for the treatment of adult women with HER2-positive breast cancer. It is used as part of combination therapy with capecitabine, trastuzumab, or aromatase inhibitors, depending on the type and stage of the disease.

Dosage form: tablets, film-coated

ATC: L01EH01